ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Lentiviral vectors offer potent and sustained gene expression, but their in vivo use remains limited by safety concerns, particularly the risks of systemic dissemination and insertional mutagenesis. To address these limitations, we present a spatially confined lentiviral gene delivery method that enables safe and efficient in vivo targeted transduction of dendritic cells (DCs) via a modular injectable scaffold. By attaching lentiviral vectors encoding a tumor antigen on the surface of mesoporous silica scaffold preloaded with granulocyte-macrophage colony-stimulating factor, we create a self-assembling scaffold that recruits DCs and promotes their localized transduction. This platform minimizes systemic vector dissemination and restricts genome integration to recruited immune cells, enabling prolonged antigen expression and efficient MHC-I-mediated antigen presentation. In melanoma models, this method elicits robust antigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.